TLDR: Metly, an AI-powered intelligence platform for pharmaceutical business development, has successfully secured €520,000 in an oversubscribed pre-seed funding round. This investment, led by Encomenda, will accelerate the company’s mission to streamline and enhance pharmaceutical licensing and manufacturing partnerships globally through advanced AI technology.
Metly, a pioneering intelligence layer designed for pharmaceutical business development teams, has announced the successful closure of an oversubscribed pre-seed funding round, raising €520,000. The investment was spearheaded by Encomenda, with significant participation from Ona Capital, Dozen Investments, and a consortium of strategic angel investors, notably including Roberto Urbez, the former VP of Spain and Portugal at Bristol Myers Squibb.
This substantial capital injection is earmarked to propel Metly’s core mission: to transform the traditionally manual and fragmented process of discovering and executing pharmaceutical licensing and manufacturing partnerships. Metly’s platform leverages sophisticated AI agents to continuously scan vast amounts of public and proprietary data. This enables the identification of high-fit opportunities, assesses their strategic alignment, and facilitates direct connections with relevant partners, significantly shortening the timelines required to bring new pharmaceutical products to market.
Lydia Taranilla, co-founder of Metly, emphasized the critical role of business development teams in the pharmaceutical sector. “Business development teams sit at the heart of pharma strategy. They shape portfolios, drive partnerships, and enable long-term growth, but they’ve been underserved by technology for years. Metly is changing that. We’re giving BD teams the speed, visibility, and intelligence they need to act faster and smarter in an increasingly complex market,” she stated. The platform aims to replace reliance on personal contacts, industry events, and spreadsheets with a more efficient, AI-driven approach.
Also Read:
- Nexxa.ai Secures $4.4 Million Pre-Seed Funding to Advance AI for Industrial Engineering
- LeadStory Secures $2.75 Million Seed Funding to Propel AI-Powered News Platform
Currently, Metly’s platform hosts an impressive database of over 35,000 licensed products from 550 global licensors. The new funding will be instrumental in scaling its artificial intelligence technology, expanding its technical and commercial teams, and accelerating its international growth, with plans for expansion into the US and China already underway. Metly’s innovative application of AI positions it alongside other notable companies like BenevolentAI and Exscientia, which are also harnessing AI to advance the broader healthcare technology sector.
